

Please note: This paper contains visible codes for electronic publishing. These will not appear in the final version and alignment of tables will be improved.

• **Please check that all queries to author [in bold type and square brackets] have been answered, including those in the references and tables. Please do not renumber the references. Any additional references can be added to the bottom of the list and unwanted references deleted from the list without renumbering. The numbering will be corrected automatically during processing**

Cannabis based products for medicinal use

We need to strengthen the evidence base and improve access for patients

Tom P Freeman, senior lecture,^{1,3} Celia Morgan, professor of psychopharmacology,^{2,3} Chandni Hindocha,³ research fellow

¹ Addiction and Mental Health Group, Department of Psychology, University of Bath, Bath, UK
Kingdom **[Q to AOK? we give just one address for each author in editorials]**

² Psychopharmacology and Addiction Lab, Department of Psychology, University of Exeter, UK

³ Clinical Psychopharmacology Unit, Research Department of Clinical, Educational, and Health Psychology, University College London, UK

Correspondence to: T P Freeman t.p.freeman@bath.ac.uk

Draft recommendations by the National Institute for Health and Care Excellence (NICE) did not recommend prescription of unlicensed cannabis based products to patients on the NHS.¹ The potential benefits for people with chronic pain were considered too small relative to costs, and the quality of evidence was rated too low to recommend use in children with severe treatment resistant epilepsy.¹ At present, the only way to get cannabis products for medicinal use in the UK is through prescriptions issued by private clinics² (which are prohibitively expensive) or the illicit market (which carries risk of prosecution as well as unknown product content, quality, and safety). Given the forceful demands for access to these products from patients and their carers,³ stronger evidence is urgently needed so that these products can be made available in situations where they are known to be effective and safe.

Cannabis based medicines vary in their content of Δ^9 -tetrahydrocannabinol (THC) and cannabidiol (CBD), which have contrasting mechanisms of action, efficacy, and safety.⁴ Some cannabis based medicines include both THC and CBD, which can interact with each other.⁵ Although evidence from randomised controlled trials is stronger for certain formulations (such as CBD for severe treatment resistant epilepsy⁴), patients have expressed a preference for treatments such as THC combined with CBD.³ Gathering evidence for such treatments is a priority and can be done by using alternative trial designs and patient registries.

Alternative trial designs

To compare varied cannabis based products efficiently, randomised controlled trials can follow adaptive designs.⁶ For example, patients can be initially randomised to one of several treatment arms such as THC, CBD, or THC combined with CBD. Interim analysis can eliminate treatment arms with poor efficacy or safety at an early stage, while randomisation continues to trial arms testing potentially effective doses.

Cannabis based products have been investigated for a wide range of medical indications, some of which may share aetiologies related to the endocannabinoid system.⁷ When multiple disorders are characterised by the same underlying mechanism, basket trials can investigate a single targeted intervention across multiple diagnostic categories.⁸ Alternatively, when different mechanisms are known to give rise to a common medical diagnosis, umbrella trials can stratify patients into different treatment arms based on the underlying disease mechanism, allocating targeted interventions to each group.⁸

Stratification can also occur at the level of the individual patient. N-of-1 trials allow randomised, double blind comparisons of active and control treatments in a cyclical manner sequentially in the same patient.⁹ These trials can establish efficacy and safety within an individual, and the results from multiple patients can be combined with meta-analysis.

Such trials have been used to evaluate cannabis based products in people with chronic pain¹⁰ and could be used for other indications such as severe treatment resistant epilepsy. They are ideally suited to situations such as treatment for compassionate reasons, unlicensed use, and for patients who fail to respond to conventional treatments,¹¹ as is often the case for cannabis based medicines. Establishing individual patients as “responders”⁹ by using n-of-1 trials could provide evidence strong enough to justify continued prescription.

Randomised controlled trials are not the only source of evidence. The European Medicines Agency and the US Food and Drug Administration have approved many drugs without randomised trials.¹² Other sources of evidence used to support drug approvals include randomised trials without a control group (for example, different doses of active drug with no placebo [**Q to A I thought randomised trials always had a control group even if it isn't a placebo—do unlicensed drugs get approved from randomised trials without a different treatment/placebo as a comparator? If not it might be less confusing to just leave this out**]), historical control studies, and observational studies.¹² Where cannabis based medicines are

provided on private prescription,² patient registries should be set up to generate observational data on real-world clinical practice and outcomes. Such data can be rapidly obtained at minimal cost and may be combined with registries outside the UK—in countries such as Canada and Israel.

Need for industry cooperation

Initial public funding to support research into cannabis based products has been offered through dedicated calls from the National Institute of Health Research. However, the UK's parliamentary Health and Social Care Committee has raised concerns about the unwillingness of industry to provide cannabis based products for research¹³ or to support or conduct clinical trials on their products. Greater support from industry could increase access to cannabis based products in a research context and help patients avoid the excessive costs of private prescriptions.² Providing access to cannabis based products in trials with informed consent can offer participants balanced information on the possible benefits and risks, which are uncertain based on the evidence at present.

The current limited evidence for cannabis based products alongside clear patient demand requires new solutions. Further trials are urgently needed, and designs such as n-of-1 trials can provide rapid evidence to inform treatment and optimise clinical outcomes for individual patients.⁹ Like all research methods, randomised trials have their limitations, such as poor generalisability. Data should also be sought from alternative methods, such as observational research using data from patient registries, which can be triangulated with other findings to develop a robust evidence base.¹⁴

Competing interests: We have read and understood BMJ policy on declaration of interests and declare TPF is funded by a senior academic fellowship from the Society for the Study of Addiction (SSA). CH is supported by the National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre. The views expressed here are those of the authors, and do not reflect those of the University of Bath, the University of Exeter, UCL, the SSA, or the NIHR.

Provenance and peer review: Commissioned; not externally peer reviewed.

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence on a worldwide basis to the BMJ Publishing Group Ltd to permit this article to be published in BMJ editions and any other BMJ PGL products and sub-

licenses such use and exploit all subsidiary rights, as set out in our licence

(bmj.com/advice/copyright.shtml).

- <eref>1 National Institute for Health and Care Excellence. Cannabis-based medicinal products. London: NICE, 2019. <https://www.nice.org.uk/guidance/indevelopment/gid-ng10124/documents></eref>
- <jrn>2 Mahase E. Medical cannabis: patients turn to private clinics because of NHS void. *BMJ* 2019;366:l5290. [PubMed doi:10.1136/bmj.l5290](https://pubmed.ncbi.nlm.nih.gov/315290/)</jrn>
- <jrn>3 Deacon H. Why I campaign for children like my son Alfie Dingley to be able to get medical cannabis. *BMJ* 2019;365:l1921. [PubMed doi:10.1136/bmj.l1921](https://pubmed.ncbi.nlm.nih.gov/311921/)</jrn>
- <jrn>4 Freeman TP, Hindocha C, Green SF, Bloomfield MAP. Medicinal use of cannabis based products and cannabinoids. *BMJ* 2019;365:l1141. [PubMed doi:10.1136/bmj.l1141](https://pubmed.ncbi.nlm.nih.gov/311141/)</jrn>
- <jrn>5 Freeman AM, Petrilli K, Lees R, et al. How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review. *Neurosci Biobehav Rev* 2019. [doi:10.1016/j.neubiorev.2019.09.036](https://doi.org/10.1016/j.neubiorev.2019.09.036).</jrn>
- <bok>6 Berry SM, Carlin BP, Lee JJ, et al. *Bayesian adaptive methods for clinical trials*. CRC Press, 2010 [doi:10.1201/EBK1439825488](https://doi.org/10.1201/EBK1439825488).</bok>
- <jrn>7 Pacher P, Kunos G. Modulating the endocannabinoid system in human health and disease--successes and failures. *FEBS J* 2013;280:1918-43. [PubMed doi:10.1111/febs.12260](https://pubmed.ncbi.nlm.nih.gov/242260/)</jrn>
- <jrn>8 Park JJH, Siden E, Zoratti MJ, et al. Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols. *Trials* 2019;20:572. [PubMed doi:10.1186/s13063-019-3664-1](https://pubmed.ncbi.nlm.nih.gov/31572/)</jrn>
- <jrn>9 Lillie EO, Patay B, Diamant J, Issell B, Topol EJ, Schork NJ. The n-of-1 clinical trial: the ultimate strategy for individualizing medicine? *Per Med* 2011;8:161-73. [PubMed doi:10.2217/pme.11.7](https://pubmed.ncbi.nlm.nih.gov/22177/)</jrn>
- <jrn>10 Notcutt W, Price M, Miller R, et al. Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies. *Anaesthesia* 2004;59:440-52. [PubMed doi:10.1111/j.1365-2044.2004.03674.x](https://pubmed.ncbi.nlm.nih.gov/13652044/)</jrn>
- <jrn>11 Schork NJ. Personalized medicine: Time for one-person trials. *Nature* 2015;520:609-11. [PubMed doi:10.1038/520609a](https://pubmed.ncbi.nlm.nih.gov/260909/)</jrn>
- <jrn>12 Hatswell AJ, Baio G, Berlin JA, Irs A, Freemantle N. Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999-2014. *BMJ Open* 2016;6:e011666. [PubMed doi:10.1136/bmjopen-2016-011666](https://pubmed.ncbi.nlm.nih.gov/261666/)</jrn>
- <eref>13 House of Commons Health and Social Care Committee. *Drugs policy: medicinal cannabis*. London 2019. <https://publications.parliament.uk/pa/cm201719/cmselect/cmhealth/1821/1821.pdf></eref>
- <jrn>14 Munafò MR, Davey Smith G. Robust research needs many lines of evidence. *Nature* 2018;553:399-401. [PubMed doi:10.1038/d41586-018-01023-3](https://pubmed.ncbi.nlm.nih.gov/310233/)</jrn>